Background: Cystic fibrosis (CF) is characterized by pancreatic destruction following the gradual obstruction of small pancreatic ducts, from the mid-trimester of gestation onwards. To date, the material causing the obstruction has not been identified. The MUC6 mucin cDNA was isolated from human stomach and has been shown to be expressed in a number of other tissues in the gastrointestinal tract, including the gall bladder and parts of the ileum and colon. Materials and Methods: We have examined the expression of MUC6 mucin in the human pancreas, both during development and postnatally, by mRNA in situ hybridization and immunocytochemistry.
INTRODUCTION
Cystic fibrosis (CF) is characterized by pancreatic insufficiency due to destruction of the pancreas. The precise cause of the destruction has generally been thought to be obstruction of the pancreatic ducts by inspissated secretions. These secretions may include mucous glycoproteins and other proteins; however, the composition of the secretions has not been defined. One of the earliest pathological manifestations of CF in utero is the deposition of periodic-acid Schiff-positive material in the fetal pancreatic ducts at about 12 weeks of gestation (1) . We have shown that the cystic fibrosis transmembrane conductance regulator (CFTR) gene (2) , that is mutated in CF, is Results: In this report we establish that MUC6 transcripts are abundant in pancreatic epithelial cells and show a very similar pattern of expression in the epithelium lining small ducts and centroacinar cells to that shown by the cystic fibrosis transmembrane conductance regulator gene (CFTR). In addition, material obstructing the pancreatic ducts of CF pancreas was shown to contain MUC6 mucin.
Conclusion:
We have identified MUC6 mucin as a significant constituent of the material obstructing the small pancreatic ducts in CF.
expressed by 12 weeks of gestation in the fetal pancreatic duct epithelium (3) (4) (5) . We have now identified MUC6 as a major pancreatic mucin that is expressed by 13 weeks of gestation and shows a pattern of distribution that is very similar to that of CFTR from this age through to adult life. The localization of expression of MUC6 mRNA has been confirmed with a polyclonal chicken antibody raised against a synthetic peptide corresponding to a tandem repeat region of MUC6 (6) . Further, we have shown in fetal CF pancreas that the MUC6 mucin is a significant constituent of the material that causes the characteristic obstruction of small ducts.
MATERIALS AND METHODS
Tissues from mid-trimester terminations were obtained with local ethical committee approval and age was determined on the basis of foot length. Pancreas samples were from four fetuses of 13 weeks gestation and one each of 16.5, 23, and 24.5 weeks. Postnatal pancreas tissues were obtained from organ donors and were from 2-, 17-and 19-year-old males. Two CF pancreases were analyzed. One was from a male AF508 homozygote who was born prematurely at 28 weeks gestation and died 21 days later from respiratory failure, at an age equivalent to 31 weeks gestation (28 + 3 weeks). The second was a 29-week intrauterine death due to intestinal rupture. The fetus was diagnosed on the basis of pathology consistent with CF and was heterozygous for AF508 and an undefined mutation. Tissues for in situ hybridization were fixed directly in 4% paraformaldehyde (pH 9.5) overnight at 40C, and embedded and frozen in liquid nitrogen prior to cutting 10-gm sections. Frozen sections were mounted onto Vectabond-treated slides (Vector Laboratories) and stored dessicated at -20°C until used.
In Situ Hybridization
In situ hybridization was carried out as described previously (5 
RESULTS

MUC6 mRNA
Abundant MUC6 mRNA expression was detected throughout the pancreatic duct epithelia and the developing acini at or by 13 weeks of gestation, the earliest fetal age examined (Fig. lA-C) . A similar pattern of expression was seen at 23 weeks ( Fig. 2A-C) . MUC6 expression patterns in a 28+3 week AF508 CF pancreas appeared normal ( Fig. 2G-I ). In postnatal pancreas (Fig. 3A-D (Fig. 3 ).
MUC6 Glycoprotein
The M6P antibody, a chicken polyclonal antibody that was raised against a MUC6 tandem repeat peptide, was used to localize the MUC6 glycoprotein in normal and CF pancreas (Fig. 4) . Panels A-D show hematoxylin and eosin-stained sections of normal 32-week gestation fetal pancreas (panels A and B) and the 28+3 week CF pancreas (panels C and D The finding that MUC6 is detected throughout the normal human pancreatic duct epithelium is significant to our understanding of the biology of mucous secretions in the pancreas. Histochemical staining of pancreatic duct epithelia has shown the presence of mucin-like glycoproteins; however, the precise composition of these secretions has not been defined. It is known that the MUC1 gene is expressed at high levels by some pancreatic epithelial cell types (10) . MUC1 mRNA is detectable in the midtrimester pancreas (11) and is evident later in gestation in the epithelium of larger pancreatic ducts (12) ; however, this mucin-like core protein is not gel-forming and it is in part cell surfaceassociated via an integral transmembrane domain. MUCI is not known to be a major component of the inspissated secretions that are found in CF pancreas and its temporal and spatial patterns of expression are distinct from CFTR. Hence, MUC1 is unlikely to be involved in the initial pathobiochemical events that lead to ductal obstruction in CF. At 13 weeks gestation, MUC3 (13) mRNA is evident in the main pancreatic duct, though not elsewhere in the pancreas (C. J. Reid and A. Harris, submitted), and hence does not account for CF pathology. MUC2 (14) , MUC3 (13) and MUC5B (15) CFTR gene coincides with that of MUC6 in the pancreas. The temporal and spatial distribution of MUC6 and CFTR transcripts show complete concordance in the pancreas (Figs. 1-3) . These results suggest that MUC6 and CFTR are expressed in the same cell types within the pancreas. We have previously verified that CFTR mRNA expressed in fetal pancreatic ducts is translated into CFTR protein (5 2-year-old normal pancreas. Further, though neither the pattern of expression nor the gross abundance of MUC6 transcripts was altered in the pancreas of a 28+3 week AF508 homozygote CF baby, post mortem, MUC6 mucin was a significant component of the material obstructing the small intralobular ducts. (These data were confirmed in a 29-week CF pancreas).
These observations may be of considerable importance to our understanding the disease process in the CF pancreas. The CFTR gene encodes a small-conductance cAMP-activated chloride ion channel (17) that is expressed at high levels in the pancreatic duct epithelium in utero and postnatally (18) . A principal physiological defect in the CF pancreas is one of failure to secrete bicarbonate ions that are essential for the normal flow of pancreatic duct secretions. One model that would explain the pathophysiology of CF in the pancreas, for which there is some physiological evidence, proposes that chloride ion efflux through CFTR is coupled to bicarbonate ion secretion via a chloride/bicarbonate exchanger in the apical membrane of the pancreatic duct cell (19) . The CF pancreatic duct fluid has reduced water and bicarbonate content (20) and is believed to contribute to the deposition of material in the small intralobular ducts. The composition of these deposits has not been characterized, although it has been suggested that they may contain secreted proteins and/or mucus glycoproteins. We have now identified MUC6 as a significant constituent of these ductal deposits. Future experiments will determine the relationship between altered CFTR functioning and the solubility of MUC6. In summary, the identification of MUC6 as a major pancreatic mucin may have significant implications for the further investigation of a number of important pancreatic diseases, including cystic fibrosis and chronic pancreatitis.
